Seizure characteristics and outcomes in patients with pleomorphic xanthoastrocytoma
These findings indicate that <i>BRAF</i>-mutated and <i>BRAF</i>-wildtype PXAs have distinct epilepsy phenotypes. Further investigation of the interplay between tumor biology and seizures may help guide counseling and targeted therapeutic strategies for PXA-related epilepsy.
Authors
- Kevin Xie (ORCID: https://orcid.org/0000-0003-1849-2085)
- Stephen Bagley (ORCID: https://orcid.org/0000-0002-7117-0539)
- Arati Desai (ORCID: https://orcid.org/0000-0002-4849-4703)
- Patrick Y. Wen (ORCID: https://orcid.org/0000-0002-0774-7700)
- Tara Jennings
- Nishant Sinha (ORCID: https://orcid.org/0000-0002-2090-4889)
- Steven Tobochnik (ORCID: https://orcid.org/0000-0001-9071-8398)
- Colin A. Ellis (ORCID: https://orcid.org/0000-0003-2152-8106)
- Sharon Xiangwen Xie (ORCID: https://orcid.org/0000-0002-7886-4103)
- Daniel J. Zhou (ORCID: https://orcid.org/0000-0002-0154-8348)
- David A. Reardon (ORCID: https://orcid.org/0000-0001-6674-0157)
- Kathryn A. Davis (ORCID: https://orcid.org/0000-0002-7020-6480)
- Joel M. Stein (ORCID: https://orcid.org/0000-0002-0741-1780)
Institutions
- Dana-Farber Cancer Institute (US)
- Translational Therapeutics (United States) (US)
- Institute for Medical Informatics and Biostatistics (CH)
- University of Pennsylvania (US)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/noajnl/vdaf134
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Gilead Sciences
- Dana-Farber Cancer Institute
- Novocure
- Incyte
- Servier
- Epilepsy Society
- National Institutes of Health
- National Human Genome Research Institute
- National Institute of Neurological Disorders and Stroke